Derivatives of erythromycin with modifications at their C-6 position are generally sought for their increased stability at acid pH, which in turn may confer improved pharmacological properties. A recombinant mutant of the erythromycin-producing bacterium, Saccharopolyspora erythraea, produced an erythromycin derivative, 6-deoxyerythromycin A, that could not be obtained readily by chemical synthesis. This product resulted from targeted disruption ofthe gene, designated eryF (systematic nomenclature, CYP107), that apparently codes for the cytochrome P450, 6-deoxyerythronolide B (DEB) hydroxylase, which converts DEB to erythronolide B (EB). Enzymes normally acting on EB can process the alternative substrate DEB to form the biologically active erythromycin derivative lacking the C-6 hydroxyl group. PREPARATION OF MODIFIED ANTIBIotics in cases where the parent molecule is complex and polyfunctional can be achieved by alteration of the antibiotic's biosynthetic pathway. Mutasynthesis (1) has been practiced for many years. More recently, genetic engineering has been useful in the formation of novel hybrid antibiotics (2, 3) . We have used recombinant DNA technology to produce an erythromycin (Er) derivative that was not readily obtainable through chemical means but that was desired for pharmacological analyses.
Integrative plasmids have been used in Saccharopolyspora erythraea for targeted gene disruption in the elucidation of the organization of genes in the Er cluster (4) (5) (6) quently this process results in the generation of stable mutants that no longer produce Er. In this study, integrants were analyzed in a relatively uncharacterized region of the gene cluster between the eryH and eryG loci (6) . Two strains so generated were distinguishable from the others by the production of a new metabolite, which was identified initially as a single spot by thin-layer chromatography (TLC) ( Fig. 1) .
One mutant was chosen for further analysis, and the new metabolite was isolated from its growth medium and purified (7). Fast atom bombardment mass spectrometry revealed that the metabolite had a molecular mass of 718 daltons, and 'H and`3C nuclear magnetic resonance (8) indicated that the structure 6-deoxyerythromycin (deoxy Er) A ( Fig. 2A ). Other components of the culture broth were separated and purified, and their structures were determined. They comprised the analogous biosynthetic congeners to Ers B. C, and D. A family of minor components, the 6-deoxy-15-norerythromycins (nor Ers) A, B, C, and D ( Fig. 2A ) was also isolated, separated, and characterized spectrally. These minor components presumably arose from the incorporation of acetyl coenzyme A (CoA), rather than of propionyl-CoA, as the starter unit to the polyketide synthase (9) . The aglycone resulting from a similar aberration of polyketide biosynthesis, 8, 8a-deoxyoleandolide, has been isolated (10) .
The mutagenic plasmids used to generate these strains were found through restriction analysis to contain fragments of 500 to 1000 bp from the eryH-eryG region. It was shown by DNA blot analysis that the plasmids had inserted into the homologous region of the chromosome (Fig. 3, A and B) .
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plasmid (designated eryF) was found by nucleotide sequence analysis to contain an open reading frame of 1212 bp coding for a putative polypeptide consisting of 404 amino acids, with a calculated molecular weight of 45.1 daltons (11) . Sequence analysis of the plasmid insert revealed that the plasmid had inserted internally to the eryF open reading frame and close to the NH2-terminus, an event that would be predicted to disrupt the function of the gene (Fig. 3C ).
Computer-assisted homology searches of the GenEMBL databases with the deduced amino acid sequence of eryF revealed a significant similarity to cytochrome P450type hydroxylases from bacterial and mammalian sources. The conservation of amino acid sequence was most striking in a 21amino acid Cys fragment ( Fig. 4 ) that is known to be associated with the heme ironbinding pocket (12) . The large number of P450 genes known and sequenced thus far constitute a gene superfamily (12) . On the basis of the criterion of Nebert and coworkers (13), in which members of the same P450 family must have .36% amino acid identity, eryF falls into a new P450 gene family and is given the systematic designation CYP107. The partial gene structure surrounding eryF is also shown ( Fig. 3C ) and is suggestive of an operon containing eryF and at least two other open reading frames. Immediately upstream and possibly translationally coupled (14) to eryF is an open reading frame that we propose corresponds to the (6) . That eryH lies upstream of eryF is consistent with the apparent polarity of mutations in eryH on eryF, and with eryH involvement in synthesis or attachment of mycarose, a function shared with eryBI and eryBII genes (6) . Immediately downstream and also translationally coupled to eryF is an open reading frame ORF, which bears significant homology in its deduced amino acid sequence to previously reported S-acyl fatty acid synthase thioesterases (15) . Convergent to ORF is a fourth open reading frame, designated eryG in accordance with results (4) showing that the eryG transcript and an eryG insertion mutation overlap the Pst I site Pb (Fig.  3C ). Finally, an unusual 24-bp overlap in the 3' coding sequences of ORF and eryG was identified. The finding that eryF encodes a cytochrome P450 hydroxylase is consistent with the production of 6-deoxyEr A by the eryF mutant. Inactivation of the C-6 hydroxylase by plasmid-mediated gene disruption of eryF apparently results in a bypass at step 2 and the production of 6-deoxyEr A as a "shunt" metabolite ( Fig. 5 ). This indicates that the enzymes for the latter steps of the pathway do not discriminate against substrates with variations at C-6. Our results are also consistent with previous biochemical analyses, which indicate that a cytochrome P450-type hydroxylase is involved at step 2 Fig. 5 . The 6-deoxyEr A biosynthetic pathway (left) and the Er A biosynthetic pathway [right, (9) ]. A mutation in step 2, eryF (indicated by ,), allows 6-deoxyerythronolide B (DEB) to bypass the C-6 hydroxylation reaction and proceed directly to step 3, ultimately resulting in the formation of 6-deoxyEr A instead of Er A. Abbreviations: 7 prop, seven three-carbon-unit starter molecules, derived from proprionate; dMEB, 6-deoxy-3-a-mycarosylerythronolide B. The numbers in boxes indicate the step number in the pathway. Double arrows at steps 5 and 6 indicate that these reactions can occur in either order, although the preferred route is step 5, then step 6.
of the biosynthetic pathway (9, 16) .
The C-6 hydroxyl group is involved in the acid-catalyzed decomposition pathway of erythromycin ( Fig. 2B) , in which the biologically inactive derivative, anhydroerythromycin (anhydroEr) is rapidly formed at the pH of the stomach (17) . Semisynthetic derivatives that are modified at C-6 or the participating C-9 ketone are unable to undergo this undesirable reaction (18) . One example, 6-0-methylerythromycin A (clarithromycin), has shown improved in vitro and in vivo activity (19, 20) , and is being used clinically. The preliminary results from this study of 6-deoxyEr A show that it is acid-stable like clarithromycin (21) , but, unlike clarithromycin, it is twoto fourfold less active than Er in vitro (22) . Upon oral administration in mice, however, where acid stability is an important factor, 6-deoxyEr A was as efficacious as Er A against three pathogenic strains (23).
The mutant that we created and characterized could have been isolated from classical mutational procedures but it was not, possibly because of the small size of the eryF target and the large numbers of survivors of mutagenesis that would have to be screened by TLC for the mutant to be found (24) . This points to an advantage of the targeted mutagenic approach (6) : much less screening is involved, because of the clustering of antibiotic biosynthetic genes, and, apparent-ly, a greater diversity of mutant phenotypes can be uncovered. Clusters of genes for antibiotic biosynthesis have been uncovered in a variety of actinomycetes (25) ; therefore, the approach described here for the Erproducer could be extended to those species for development of new antibiotics. 7. The mutant was cultivated for 5 days at 32'C in 50-mi volumes of T broth (bactotryptone, 12 g; yeast extract, 24 g; glycerol, 4 ml; distilled water, 1 liter) in 500-mi Erlenmeyer flasks and aerated by shaking at 240 rpm, 5-cm displacement. On day 5, the cultures were combined and the cells were removed by centrifugation. To extract the antibiotic, we adjusted the broth to pH 10 with 4 M sodium hydroxide and then mixed with an equal volume of ethyl acetate. The concentrated extract was partitioned between 150 mi each of heptane and methanol, and the lower (methanol) layer was concentrated to a residue. The residue was purified by chromatography on a Sephadex LH-20 column (3.2 cm by 75 cm), which was preswollen, loaded, and eluted with a mixture of chloroform, heptane, and ethanol (10:10:1, v/v/v). Fractions (10 ml) were collected and analyzed by TLC (6) . Fractions giving magenta spots with about the same Rf as erythromycins were collected and pooled according to Rf. These fraction pools were each concentrated to solid residues, which were individually subjected to highspeed countercurrent chromatography with an Ito Coil Planet Centrifuge [P.C., Inc.; for separation of complex mixtures of macrolides, as described (3)] in a mixture of carbon tetrachloride, methanol, and 0.01 M aqueous potassium phosphate buffer (pH 7.0) (1:1:1). More hydrophilic congeners were separated by further chromatography (upper-phase mobile, forward spin, tail as inlet, flow rate approximately 3 m/min at 800 rpm, about 60% stationary phase retention). For more lipophilic congeners, the lower phase was used as the mobile phase by reversal of the spin. This led to 85% retention of the stationary phase. Fractions (10 ml) containing a single component were combined, concentrated, and partitioned between methylene chloride and dilute ammonium hydroxide (pH 9). The methylene chloride layers were concentrated to solid residues, and these were used for spectral analyses. 
